Testing moléculaire EGFR, PDL1 et ALK dans les carcinomes broncho-pulmonaires au CHU Mohammed VI de Marrakech : Etude prospective de 2 ans.

dc.contributor.advisorL. AMRO
dc.contributor.authorHajar BAHRI
dc.date.accessioned2023-09-19T14:15:27Z
dc.date.accessioned2026-01-28T12:21:49Z
dc.date.available2023-09-19T14:15:27Z
dc.date.issued2022
dc.description.collaboratorH. RAIS
dc.description.collaboratorM. KHOUCHANI
dc.identifier.urihttps://toubkal.imist.ma/handle/123456789/22048
dc.identifier.urihttps://doi.org/10.83129/toubkal-219
dc.language.isofr
dc.publisherFaculté de Médecine et de Pharmacie, Marrakechfr_FR
dc.publisherSciences médicalesfr_FR
dc.subject.otherMédecine interne
dc.subject.specificCancer broncho-pulmonaire
dc.subject.specificImmunohistochimie
dc.subject.specificBiologie moléculaire EGFR
dc.subject.specificALK
dc.subject.specificPDL-1
dc.titleTesting moléculaire EGFR, PDL1 et ALK dans les carcinomes broncho-pulmonaires au CHU Mohammed VI de Marrakech : Etude prospective de 2 ans.fr_FR

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
these48-22.pdf
Size:
3.41 MB
Format:
Adobe Portable Document Format